Recent developments include securing broad U.S. patents expanding the neuromodulation platform, reporting preclinical and clinical data on nerve-targeted therapies, entering a $2.6 million warrant inducement agreement, and showcasing clinical data at major oncology symposiums.

• Autonomix secured a broad U.S. patent to expand its precision neuromodulation platform [N1].
• The company reported preclinical data on renal denervation after receiving a U.S. patent, with a subsequent stock price decline [N3].
• Autonomix secured a U.S. patent for an overactive bladder diagnosis and treatment platform [N4].
• Entered into a $2.6 million warrant inducement agreement, issuing new warrants exercisable at $5.75 per share [N5].
• Showcased compelling proof-of-concept clinical data demonstrating rapid and durable pain relief across all stages of pancreatic cancer at the 2026 ASCO Gastrointestinal Cancers Symposium [N6].
• Announced successful initial trial phase and plans for market expansion study in pancreatic cancer pain management [N7].
• Reported successful Phase 1 trial results for pain management in pancreatic cancer and initiated Phase 2 study [N8].

Autonomix Medical's technology platform offers a novel approach to nerve-targeted therapies by combining precise neural signal sensing with radiofrequency ablation, potentially addressing unmet needs in pancreatic cancer pain management and other nerve-related disorders. The company's expanding patent portfolio strengthens its intellectual property position. Positive early clinical data demonstrating rapid and durable pain relief support the platform's potential clinical utility. Successful capital raises and regained Nasdaq compliance provide operational runway to advance clinical trials and development. If clinical and regulatory milestones are met, the platform could offer differentiated treatment options in a challenging therapeutic area.

Autonomix Medical faces significant risks as a development-stage company with no current revenues and ongoing net losses. The technology remains in early clinical stages with variability in outcomes leading to paused enrollment and procedural refinements. The company requires substantial additional capital, estimated at $25 to $30 million, to fund operations through commercialization, with uncertainty around capital availability and terms. Regulatory, clinical, and competitive risks remain, including potential delays or failures in clinical trials, challenges in market adoption, and evolving competitive landscape. Nasdaq listing compliance and stock price volatility add further risk to shareholder value and liquidity.

Autonomix Medical's moat is primarily based on its proprietary catheter-based neural sensing and radiofrequency ablation technology, supported by a portfolio of U.S. patents that protect its precision neuromodulation platform and treatment methods. The integration of high-sensitivity neural signal detection with targeted ablation aims to improve treatment precision and consistency, potentially differentiating it from conventional nerve-targeted therapies. The company's early clinical data and ongoing development efforts contribute to its technological differentiation. However, as a development-stage company, its competitive position depends on successful clinical validation, regulatory approvals, and commercialization, with risks from competition, capital requirements, and clinical trial outcomes.

• Capital Requirements and Liquidity Risk: The company requires significant additional financing to continue operations and fund clinical trials, with current cash sufficient only into early 2027. Failure to raise capital on acceptable terms could force scaling back operations or delay development.
• Clinical and Regulatory Risk: The technology is in early clinical stages with paused enrollment due to variability in outcomes. Clinical trial results and regulatory approvals are uncertain and critical to future commercialization.
• Market and Competitive Risk: The medical device and neuromodulation markets are competitive and rapidly evolving. New technologies or competitors could impact the company's market opportunities and adoption.
• Nasdaq Listing Compliance Risk: The company recently regained compliance with Nasdaq listing rules after a reverse stock split but remains subject to minimum market value requirements, with potential adverse consequences if compliance is lost.

• Autonomix Medical, Inc. is a development-stage medical device company focused on nervous system disorder treatments using a catheter-based neural sensing and RF ablation platform.
• The technology integrates high-sensitivity neural signal detection with targeted radiofrequency ablation to enable a 'sense, treat, verify' approach.
• Preclinical studies show the ability to detect nerve signals and confirm ablation effects; early clinical proof-of-concept studies have been conducted for pancreatic cancer pain management.
• The company has secured multiple U.S. patents expanding its neuromodulation platform and treatment technologies, including for overactive bladder and renal denervation.
• Recent clinical data demonstrated rapid and durable pain relief in pancreatic cancer patients across disease stages.
• The company has raised capital through warrant inducements and exercises, with $3.46 million cash reported as of June 30, 2026, and liquidity ratios indicating sufficient resources into early 2027.
• Net loss for Q1 2027 was $2.73 million, with R&D and G&A expenses slightly decreased year-over-year.
• Management includes CEO Brad Hauser, CMO Dr. Robert Schwartz, CTO Landy Toth, CFO Trent Smith, and Executive Chairman Walter V. Klemp.
• The company is listed on Nasdaq and recently regained compliance with the Bid Price Rule after a reverse stock split.
• Additional capital of approximately $25 to $30 million is estimated to be required to fund operations through commercialization of the first indication.